Hangzhou Tigermed Consulting Co., Ltd, a leading clinical contract research organization (CRO) in China, recently selected Oracle Health Sciences InForm to more efficiently develop, conduct and manage electronic data capture (EDC)-based clinical trials on behalf of its clients.
Being an existing user of Oracle Clinical for their paper trials, Tigermed selected Oracle Health Sciences InForm to extend its competitive edge in the local market and support international expansion with a trusted and highly scalable, leading clinical data management platform.
With its standardized feature sets, comprehensive data capture functionality and multi-language capabilities, Oracle Health Sciences InForm provides Tigermed with a robust solution to meet the needs of China’s clinical trial sponsors – while allowing for seamless expansion into the global marketplace.
“By adopting Oracle Health Sciences InForm, we will be positioned to support the growing number of clinical trials conducted in China, and their sponsors, with leading clinical data management capabilities,” said Wen Chen, vice president, Tigermed. “Further, with Oracle’s training and support through the Oracle CRO Advantage Program, we can maximize our investment in Oracle Health Sciences solutions – securing the confidence of a growing number of clinical trial sponsors.”
Oracle Health Sciences InForm’s comprehensive data review capabilities will enable Tigermed to gain better control over its data and generate efficiency and productivity gains in data management and remote monitoring.
Using Oracle Health Sciences InForm, Tigermed will be able to develop flexible source verification strategies that allow rapid changes to the source verification workload based on data quality.
In addition, Tigermed will be able to take advantage of Oracle Health Sciences Central Designer’s centralized study design environment to accelerate trial development and increase trial efficiency.
“With a heavy focus on growth, Tigermed requires a solution that will extend its clinical data management and EDC capabilities,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “Tigermed relies on Oracle Health Sciences’ world-class solutions, including Oracle Health Sciences InForm and Oracle Health Sciences Central Designer, to enable rapid trial set up, data accuracy, clinical trial productivity and informed decision making – helping Tigermed to gain the trust of both local and global trial sponsors.”
To differentiate its business and gain a competitive advantage, Tigermed joined the Oracle CRO Advantage Program – a program that provides a framework for driving CRO success with Oracle Health Sciences products through training, sales and marketing support and tools and regular communications on Oracle products and strategy.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.